Table 1.
Associations of genetically predicted higher vitamin B12 concentrations with cancer in sensitivity analyses.
| Cancer | I2 (%) | P (I2) | Weighted median | MR-Egger | |||||
|---|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | p | OR | 95% CI | p | pintercept | |||
| Overall cancer (UKBB) | 15 | 0.323 | 1.02 | 0.98–1.05 | 0.394 | 0.98 | 0.94–1.03 | 0.403 | 0.184 |
| Overall cancer (FinnGen) | 16 | 0.142 | 0.94 | 0.86–1.02 | 0.130 | 0.97 | 0.82–1.14 | 0.691 | 0.780 |
| Digestive system cancer (UKBB) | 17 | 0.207 | 1.06 | 0.97–1.16 | 0.192 | 1.00 | 0.90–1.11 | 0.955 | 0.007 |
| Digestive system cancer (FinnGen) | 9 | 0.630 | 1.00 | 0.83–1.21 | 0.987 | 1.04 | 0.77–1.41 | 0.805 | 0.859 |
| Oesophageal (UKBB) | 8 | 0.769 | 1.18 | 0.92–1.52 | 0.189 | 1.17 | 0.86–1.61 | 0.320 | 0.848 |
| Oesophageal (FinnGen) | 13 | 0.271 | 1.77 | 0.74–4.21 | 0.197 | 4.23 | 1.05–16.94 | 0.042 | 0.036 |
| Gastric (UKBB) | 10 | 0.672 | 1.03 | 0.78–1.36 | 0.846 | 0.89 | 0.63–1.27 | 0.526 | 0.098 |
| Gastric (FinnGen) | 11 | 0.458 | 0.91 | 0.52–1.58 | 0.727 | 0.86 | 0.36–2.10 | 0.748 | 0.691 |
| Pancreatic (UKBB) | 15 | 0.302 | 1.14 | 0.92–1.43 | 0.237 | 1.03 | 0.77–1.39 | 0.845 | 0.955 |
| Pancreatic (FinnGen) | 13 | 0.304 | 0.63 | 0.36–1.08 | 0.092 | 0.60 | 0.23–1.58 | 0.303 | 0.870 |
| Colorectal (UKBB) | 14 | 0.385 | 1.10 | 0.98–1.22 | 0.103 | 1.05 | 0.92–1.20 | 0.462 | 0.078 |
| Colorectal (FinnGen) | 3 | 0.984 | 1.22 | 0.96–1.54 | 0.100 | 1.20 | 0.80–1.80 | 0.381 | 0.961 |
CI confidence interval, OR odds ratio, UKBB UK Biobank.
The I2 (%) presents the heterogeneity among SNPs in each analysis and the pintercept is the p-value for the intercept in MR-Egger.